Literature DB >> 22995522

White adipose tissue apolipoprotein C-I secretion in relation to delayed plasma clearance of dietary fat in humans.

Hanny Wassef1, Huda Salem, Simon Bissonnette, Alexis Baass, Robert Dufour, Jean Davignon, May Faraj.   

Abstract

OBJECTIVE: White adipose tissue (WAT) dysfunction is characterized by delayed clearance of dietary triglyceride-rich lipoproteins (TRL). We reported that apolipoprotein (apo) C-I, a transferable apolipoprotein that inhibits lipoprotein lipase activity when bound to TRL, was produced by a human adipocyte model. Thus, we aimed to determine whether increased WAT apoC-I secretion is related to delayed dietary fat clearance in humans. METHODS AND
RESULTS: After the ingestion of a (13)C-triolein-labeled high-fat meal, postmenopausal obese women with high-fasting WAT apoC-I secretion (median >0.81 μmol/L per g/4 hours, n=9) had delayed postprandial plasma clearance of (13)C-triglyceride and (13)C-nonesterified fatty acids over 6 hours compared with controls. WAT apoC-I secretion over 4 hours correlated with fasting total and non-high-density lipoprotein apoC-I but not with high-density lipoprotein apoC-I and was the primary predictor of 4-hour postprandial increases in TRL apoC-I. Correction for TRL apoC-I eliminated the association of WAT apoC-I with 6-hour area under the curve of plasma (13)C-triglyceride; correction for insulin sensitivity or inflammation did not. Finally, in addition to apoC-I, WAT secreted considerable amount of apoC-II, apoC-III, and apoE over 24 hours; however, only WAT apoC-I secretion was associated with 6-hour area under the curve of plasma (13)C-triglyceride.
CONCLUSIONS: Increased WAT apoC-I secretion in obese women is associated with delayed postprandial dietary fat clearance mediated by increased TRL apoC-I. Thus, we hypothesize that reducing WAT apoC-I secretion ameliorates WAT dysfunction and associated cardiometabolic risks in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995522     DOI: 10.1161/ATVBAHA.112.300306

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  The Association of Polyunsaturated Fatty Acid δ-5-Desaturase Activity with Risk Factors for Type 2 Diabetes Is Dependent on Plasma ApoB-Lipoproteins in Overweight and Obese Adults.

Authors:  Valérie Lamantia; Simon Bissonnette; Viviane Provost; Marie Devaux; Yannick Cyr; Caroline Daneault; Christine Des Rosiers; May Faraj
Journal:  J Nutr       Date:  2019-01-01       Impact factor: 4.798

2.  Low density lipoprotein delays clearance of triglyceride-rich lipoprotein by human subcutaneous adipose tissue.

Authors:  Simon Bissonnette; Huda Salem; Hanny Wassef; Nathalie Saint-Pierre; Annie Tardif; Alexis Baass; Robert Dufour; May Faraj
Journal:  J Lipid Res       Date:  2013-02-17       Impact factor: 5.922

3.  Simultaneous LC/MS/MS quantification of eight apolipoproteins in normal and hypercholesterolemic mouse plasma.

Authors:  Richard Wagner; Julia Dittrich; Joachim Thiery; Uta Ceglarek; Ralph Burkhardt
Journal:  J Lipid Res       Date:  2019-02-05       Impact factor: 5.922

4.  WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.

Authors:  Yannick Cyr; Hanny Wassef; Simon Bissonnette; Valerie Lamantia; Jean Davignon; May Faraj
Journal:  J Lipid Res       Date:  2016-04-03       Impact factor: 5.922

5.  Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.

Authors:  Yannick Cyr; Valérie Lamantia; Simon Bissonnette; Melanie Burnette; Aurèle Besse-Patin; Annie Demers; Martin Wabitsch; Michel Chrétien; Gaétan Mayer; Jennifer L Estall; Maya Saleh; May Faraj
Journal:  Physiol Rep       Date:  2021-02

6.  Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes independent of obesity in humans.

Authors:  S Bissonnette; N Saint-Pierre; V Lamantia; Y Cyr; H Wassef; M Faraj
Journal:  Nutr Diabetes       Date:  2015-09-28       Impact factor: 5.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.